Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) shot up 1.6% during mid-day trading on Friday . The company traded as high as $7.17 and last traded at $6.91, with a volume of 607,755 shares. The stock had previously closed at $6.80.

A number of research firms have recently issued reports on AVXL. Zacks Investment Research cut shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Maxim Group reiterated a “positive” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Monday, April 25th. Finally, FBR & Co began coverage on shares of Anavex Life Sciences Corp. in a research note on Tuesday, March 29th. They issued an “outperform” rating and a $10.00 price objective for the company.

The firm’s market capitalization is $252.11 million. The firm has a 50 day moving average of $5.20 and a 200 day moving average of $4.81.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.10. On average, equities analysts expect that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.